Stock listing

BOATS:NDRA ENDRA Life Sciences Inc. Stock

US listing (BOATS) of ENDRA Life Sciences Inc. · home listing NASDAQ:NDRA

Follow ENDRA Life Sciences Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:NDRA

$3.58 USD -0.46 (-11.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NDRA

Past year -36.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.42 – $3.73 USDNov 20, 2026
Volume
15,674 sharesNov 20, 2026
Market cap
$5.36M USDAt the close on Nov 20, 2026 · price × 1.50M shares outstanding
52-week range
$2.96 – $6.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$159,719 USDMedian day 14,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ENDRA Life Sciences Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NDRA · Home$3.575 USD-0.46 (-11.4%)15,674$3.70$3.725$3.42$4.035Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NDRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.575-0.46-11.4%$3.70$3.725$3.4215,674
$4.035+0.115+2.9%$3.86$4.055$3.52513,925
$3.92-0.50-11.3%$4.405$4.41$3.4416,967
$4.42+0.01+0.2%$4.46$4.46$4.324,471
$4.41-0.23-5.0%$4.51$4.52$4.414,552
$4.64-0.129-2.7%$4.59$4.96$4.597,418
$4.769-0.0010.0%$4.77$4.80$4.6375,435
$4.77-0.07-1.4%$4.78$5.14$4.7710,135
$4.84+0.11+2.3%$4.75$4.892$4.714,125
$4.73-0.275-5.5%$4.98$4.98$4.701,161
$5.005+0.065+1.3%$4.98$5.005$4.0017,138
$4.94+0.08+1.6%$4.75$4.96$4.757,370
$4.86+0.06+1.3%$4.83$4.945$4.7453,740
$4.80+0.05+1.1%$4.64$4.885$4.645,777
$4.75-0.13-2.7%$4.85$4.86$4.72310,517
$4.88+0.14+3.0%$4.91$5.185$4.6914,490
$4.74-0.221-4.5%$5.01$5.01$4.5810,269
$4.961+0.141+2.9%$4.80$5.00$4.7624,279
$4.82+0.02+0.4%$4.83$4.98$4.73512,860
$4.80+0.02+0.4%$4.68$4.80$4.6554,500
$4.78+0.10+2.1%$4.80$4.915$4.56210,800
$4.68+0.21+4.7%$4.48$4.795$4.4817,400
$4.47-0.28-5.9%$4.61$4.995$4.2620,300
$4.75+0.01+0.2%$4.83$4.99$4.669,500
$4.74-0.36-7.1%$4.81$5.00$4.7414,300
$5.10+0.325+6.8%$4.95$5.14$4.9011,000
$4.775-0.265-5.3%$5.00$5.099$4.7315,000
$5.04-0.095-1.9%$5.07$5.10$5.032,900
$5.135-0.325-6.0%$5.65$5.65$5.0515,800
$5.46-0.47-7.9%$5.81$6.015$5.3223,100
$5.93-0.13-2.1%$6.00$6.48$5.8112,900
$6.06+0.02+0.3%$5.99$6.17$5.917,500
$6.04-0.27-4.3%$6.40$6.40$6.0214,800
$6.31+0.25+4.1%$6.09$6.31$6.0129,500
$6.06+0.18+3.1%$5.96$6.11$5.91539,700
$5.88-0.08-1.3%$6.112$6.112$5.7723,400
$5.96+0.08+1.4%$6.05$6.06$5.7927,700
$5.88+0.08+1.4%$5.76$6.17$5.6822,100
$5.80-0.24-4.0%$5.94$6.39$5.7025,800
$6.04+0.11+1.9%$5.97$6.315$5.84137,400
$5.93-0.57-8.8%$6.63$6.63$5.9032,400
$6.50+0.27+4.3%$6.29$6.67$6.1756,800
$6.23-0.08-1.3%$6.37$6.37$5.91540,700
$6.31+0.81+14.7%$5.60$6.44$5.4136,500
$5.50+0.081+1.5%$5.37$5.50$5.1017,800
$5.419+0.119+2.2%$5.31$5.55$5.0477,600
$5.30-0.30-5.4%$5.32$5.671$4.90170,800
$5.60-0.27-4.6%$6.02$6.15$5.5633,900
$5.87+0.25+4.4%$5.82$5.90$5.5025,500
$5.62-0.165-2.9%$5.84$5.84$5.555,800
$5.785-0.045-0.8%$5.74$6.32$5.5677,500
$5.83-0.075-1.3%$5.77$6.552$5.7572,100
$5.905-0.145-2.4%$6.094$6.10$5.9052,900
$6.05+0.37+6.5%$5.70$6.365$5.7020,600
$5.68-0.78-12.1%$6.45$6.45$5.66624,500
$6.46+1.19+22.6%$5.05$6.75$5.05135,900
$5.27+0.265+5.3%$5.07$5.65$4.88395,800
$5.0050.000.0%$5.005$5.005$4.811,200
$5.005-0.40-7.4%$5.59$5.77$5.00524,500
$5.405-0.035-0.6%$5.50$5.60$5.2849,900
$5.44+0.69+14.5%$4.46$5.44$4.17211,400
$4.75+0.19+4.2%$4.47$4.97$4.4713,600
$4.56+0.07+1.6%$4.57$4.90$4.4657,300
$4.49-0.095-2.1%$4.63$4.70$4.1927,400
$4.585+0.065+1.4%$4.445$4.82$4.4457,600

Splits

3 splits since 2022 · NASDAQ:NDRA · every price before a split is adjusted for it

DayRatioWhat
1-for-35Consolidation
1-for-50Consolidation
1-for-20Consolidation
Ticker
BOATS:NDRA
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All ENDRA Life Sciences Inc. news

ENDRA Life Sciences Inc. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
14 in the last 12 months · 141 in all · newest Nov 16, 2026 · oldest 2019
Calls
18 calls with a replay · 18 with a transcript · latest Aug 22, 2024
Decks
12 decks · latest Sep 9, 2026

Where ENDRA Life Sciences Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NDRA · Home listingNASDAQUnited StatesUSD
BOATS:NDRA · This pageBOATSUnited StatesUSD

Valuation

Price/book 1.0× against a median of 0.7×: 6th lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.85M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.07

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ENDRA Life Sciences Inc. · NASDAQ:NDRAUS$5.36MUS$3.85Mn/an/an/a1.0×n/a0.0×1.07
Izotropic Corp. · CSE:IZOUS$6.30MUS$6.26Mn/an/an/an/an/an/a0.21
Accuray Incorporated · NASDAQ:ARAYUS$6.20MUS$65.61Mn/a0.2×n/a0.1×−4.4%1.9×2.46
NeuroOne Medical Technologies Corporation · NASDAQ:NMTCUS$5.94MUS$3.89Mn/a0.4×n/a1.6×−78.6%0.0×1.07
Neola Medical AB · OMXSTO:NEOLAUS$5.46MUS$5.07Mn/an/an/a0.6×n/a0.0×n/a
MEKICS Co., Ltd. · KRX:058110US$5.23MUS$2.04M6.6×0.2×1.3×0.2×7.7%0.1×n/a
PT Hetzer Medical Indonesia Tbk · IDX:MEDSUS$5.16MUS$5.45Mn/an/an/a1.8×n/a0.1×n/a
Regentis Biomaterials Ltd. · AMEX:RGNTUS$5.05M−US$3.90Mn/an/an/a0.7×n/a0.0×2.00
SeaStar Medical Holding Corporation · NASDAQ:ICUUS$4.97MUS$981,429n/a0.5×n/a10.6×−678.2%0.0×1.44
WORK Medical Technology Group LTD · NASDAQ:WOKUS$4.84MUS$8.21Mn/a0.8×n/a0.2×−10.9%0.2×2.76
Kelyniam Global, Inc. · OTC:KLYGUS$4.56MUS$4.84Mn/a1.4×31.9×6.6×−6.0%0.6×1.15
Median of the othersUS$5.19MUS$4.96M6.6×0.4×16.6×0.7×−8.4%0.1×1.44

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
25.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.54 · 1 analyst

Team and board

Officers

OfficerRole
Alexander TokmanCEO & Director
Richard JacrouxChief Financial Officer
Scott SoberHead of Operations
Ziad RouagHead of Clinical and Regulatory

Board

DirectorRole
Alexander TokmanCEO & Director
Anthony DiGiandomenicoDirector
Lou BaseneseDirector
Michael HarshDirector

Events

Calls

CallWhenStatus
ENDRA Life Sciences (NASDAQ:NDRA) Q2 2024 Earnings CallThu, Aug 22, 2024 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q1 2024 Earnings CallTue, May 14, 2024 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q4 2023 Earnings CallThu, Mar 28, 2024 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q3 2023 Earnings CallTue, Nov 14, 2023 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q2 2023 Earnings CallMon, Aug 14, 2023 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q1 2023 Earnings CallMon, May 15, 2023 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q4 2022 Earnings CallTue, Mar 14, 2023 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q3 2022 Earnings CallMon, Nov 14, 2022 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q2 2022 Earnings CallMon, Aug 15, 2022 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q1 2022 Earnings CallThu, May 12, 2022 · 4:30 PM ETReplay
All 18 calls
CallWhenStatus
ENDRA Life Sciences (NASDAQ:NDRA) Q4 2021 Earnings CallWed, Mar 30, 2022 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q3 2021 Earnings CallMon, Nov 15, 2021 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q2 2021 Earnings CallThu, Aug 12, 2021 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q1 2021 Earnings CallMon, May 17, 2021 · 4:30 PM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q3 2020 Earnings CallMon, Nov 16, 2020 · 3:30 AM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q2 2020 Earnings CallMon, Aug 17, 2020 · 4:30 AM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q1 2020 Earnings CallThu, May 14, 2020 · 4:30 AM ETReplay
ENDRA Life Sciences (NASDAQ:NDRA) Q4 2020 Earnings CallWed, Mar 25, 2020 · 4:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−11.3%
Q2 2026Aug 14, 2026 · After close+0.5%
Q1 2026May 15, 2026 · After close+7.1%
Q3 2025Nov 14, 2025 · After close−7.5%
Q2 2025Aug 14, 2025 · After close+9.5%
Q1 2025May 15, 2025+3.2%
Q4 2024Mar 31, 2025 · Before open+1.2%
Q3 2024Nov 15, 2024 · Before open−14.2%
Q2 2024Aug 14, 2024 · After close−5.6%
Q1 2024May 14, 2024 · After close+0.3%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 28, 2024 · After close−30.5%
Q3 2023Nov 14, 2023 · After close+3.2%
Q2 2023Aug 14, 2023 · After close−8.4%
Q1 2023May 15, 2023 · After close+1.6%
Q4 2022Mar 14, 2023 · After close−3.2%
Q3 2022Nov 14, 2022 · After close
Q2 2022Aug 15, 2022 · After close
Q1 2022May 12, 2022 · After close
Q4 2021Mar 30, 2022 · After close
Q3 2021Nov 15, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Day (September 2026)Investor day29 slidesSep 9, 2026
Merger or Acquisition (June 2026)Merger or acquisition39 slidesJun 26, 2026
Investor Presentation (June 2025)Investor deck19 slidesJune 2025
Investor Presentation (January 2022)Investor deck19 slidesJan 7, 2022
Investor Presentation (March 2021)Investor deck19 slidesMar 5, 2021
Investor Presentation (January 2021)Investor deck18 slidesJan 11, 2021
Investor Presentation (December 2020)Investor deck19 slidesDec 14, 2020
Investor Presentation (September 2020)Investor deck16 slidesSep 2, 2020
Investor Presentation (June 2020)Investor deck15 slidesJun 1, 2020
Investor Presentation (December 2019)Investor deck14 slidesDec 19, 2019
All 12 decks
DeckKindSlidesDate
Investor Presentation (July 2018)Investor deck22 slidesJul 18, 2018
Investor Presentation (June 2017)Investor deck19 slidesJun 2, 2017

Open Decks

Financings

RaiseDate
Private placement of private investment in public equity (PIPE)
Closed: US$4.9M raised · US$6.57 a share · Warrants at US$6.32 for 60 months · Lucid Capital Markets
Dealers: Lucid Capital Markets (lead)
Use of proceeds: Mostly to launch a digital asset treasury and buy cryptocurrency; the rest to complete the TAEUS pilot validation imaging study on MASLD/MASH
Oct 23, 2025
At-the-market programme of common stock
Closed: US$800,000 raised
May 15, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Declared effective by the SEC on Feb 12, 2019. Filed with the SEC to go public on Nov 21, 2016.

Price range
US$5.00 to US$5.50 a unit
Units offered
1,400,000 units
Offering size
US$7 million to US$7.7 million · Units offered times the price range, worked out by 6ix
Underwriters' option
Up to 210,000 more units
Listing
NDRAU on the Nasdaq Capital Market
Underwriters
National Securities Corporation, Dougherty & Company · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 9, 2016
Filed publiclyNov 21, 2016
Amended 13 timesNewest Jan 24, 2019
Shares registered with an exchangeDec 16, 2016
Declared effective by the SECFeb 12, 2019
Final prospectus, with the priceNot yet

Filings

FilingFiled
CORRESP · Letter to the SECJun 3, 2024
CORRESP · Letter to the SECJun 3, 2024
UPLOAD · Letter from the SECApr 29, 2024
CORRESP · Letter to the SECApr 1, 2024
UPLOAD · Letter from the SECFeb 23, 2024
S-1MEF · Registration of more shares for the same offeringApr 28, 2023
CORRESP · Letter to the SECApr 24, 2023
CORRESP · Letter to the SECApr 24, 2023
UPLOAD · Letter from the SECApr 7, 2023
8-A12G · Registration of a class of sharesSep 27, 2022
All 68 filings
FilingFiled
CORRESP · Letter to the SECApr 29, 2021
UPLOAD · Letter from the SECMar 30, 2021
CORRESP · Letter to the SECJan 22, 2020
UPLOAD · Letter from the SECJan 15, 2020
CORRESP · Letter to the SECSep 11, 2019
UPLOAD · Letter from the SECSep 4, 2019
EFFECT · Notice that a registration is effectiveFeb 12, 2019
EFFECT · Notice that a registration is effectiveFeb 8, 2019
POS AM · Amendment to an effective registrationJan 24, 2019
POS AM · Amendment to an effective registrationDec 28, 2018
CORRESP · Letter to the SECAug 30, 2018
CORRESP · Letter to the SECAug 30, 2018
UPLOAD · Letter from the SECAug 22, 2018
UPLOAD · Letter from the SECAug 22, 2018
EFFECT · Notice that a registration is effectiveMay 8, 2017
S-1MEF · Registration of more shares for the same offeringMay 8, 2017
CERTNAS · Nasdaq's certificate of listingMay 4, 2017
CERTNYS · New York Stock Exchange's certificate of listingMay 4, 2017
CORRESP · Letter to the SECMay 4, 2017
CORRESP · Letter to the SECMay 4, 2017
8-A12B/A · Registration of shares for listing on an exchange, amendedMay 4, 2017
S-1/A · Registration statement, amendedMay 3, 2017
S-1/A · Registration statement, amendedMay 1, 2017
CERTNAS · Nasdaq's certificate of listingApr 18, 2017
CORRESP · Letter to the SECApr 18, 2017
CORRESP · Letter to the SECApr 18, 2017
8-A12B/A · Registration of shares for listing on an exchange, amendedApr 18, 2017
CORRESP · Letter to the SECApr 14, 2017
S-1/A · Registration statement, amendedApr 14, 2017
S-1/A · Registration statement, amendedMar 27, 2017
CORRESP · Letter to the SECJan 31, 2017
CORRESP · Letter to the SECJan 31, 2017
CORRESP · Letter to the SECJan 26, 2017
S-1/A · Registration statement, amendedJan 26, 2017
8-A12B/A · Registration of shares for listing on an exchange, amendedJan 24, 2017
CORRESP · Letter to the SECJan 24, 2017
CORRESP · Letter to the SECJan 24, 2017
S-1/A · Registration statement, amendedJan 23, 2017
S-1/A · Registration statement, amendedJan 20, 2017
S-1/A · Registration statement, amendedDec 20, 2016
8-A12B/A · Registration of shares for listing on an exchange, amendedDec 19, 2016
S-1/A · Registration statement, amendedDec 19, 2016
8-A12B · Registration of shares for listing on an exchangeDec 16, 2016
S-1/A · Registration statement, amendedDec 15, 2016
CORRESP · Letter to the SECDec 15, 2016
CORRESP · Letter to the SECDec 15, 2016
CORRESP · Letter to the SECDec 15, 2016
UPLOAD · Letter from the SECDec 14, 2016
CORRESP · Letter to the SECDec 6, 2016
S-1/A · Registration statement, amendedDec 6, 2016
UPLOAD · Letter from the SECDec 5, 2016
S-1 · Registration statementNov 21, 2016
CORRESP · Letter to the SECNov 18, 2016
UPLOAD · Letter from the SECOct 11, 2016
DRSLTR · Letter to the SEC with a draftSep 21, 2016
DRS/A · Draft registration statement, amendedSep 21, 2016
UPLOAD · Letter from the SECSep 2, 2016
DRS · Draft registration statementAug 9, 2016

Open IPO · From the cover of the amended prospectus (S-1/A) filed May 1, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000006.17K351.6K515.6K
Cost of revenue206.2K275.5K234.3K224.4K000172.8K235.9K
Gross profit-206.2K-275.5K-234.3K-224.4K006.17K178.8K279.7K
Research and development1.85M3.19M5.00M6.55M5.48M5.92M6.57M4.72M1.93M495.4K
Selling, general and administrative3.72M7.06M4.70M5.17M4.94M5.00M3.86M3.75M2.75M1.54M
Operating income-5.76M-10.8M-10.5M-13.2M-11.5M-11.5M-10.8M-9.02M-4.63M-1.79M
Depreciation and amortization44.0K46.5K123.7K96.7K116.2K99.3K80.6K68.3K61.5K64.9K
EBITDA-5.72M-10.8M-10.4M-13.1M-11.4M-11.4M-10.8M-8.95M-4.56M-1.73M
Interest expense21.5K267.1K232.4K2.36M042.6K72.0K
Income before tax-7.03M-11.5M-10.1M-13.2M-11.2M-11.7M-13.3M-9.80M-5.38M-2.78M
Income tax000000000
Net income-7.03M-11.5M-10.1M-13.2M-11.2M-11.7M-13.3M-9.80M-5.38M-2.78M
Earnings per share, basic-8.93-56.94-1,694.50-4.56-5.55-0.63-2.34-2.17-1.95-3.84
Earnings per share, diluted-8.93-56.94-2,766.85-0.63-2.34-2.17-1.95-3.84

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents762.4K3.23M2.83M4.89M9.46M7.23M6.17M6.47M5.60M145.0K
Receivables-2.62M-1.35M390.8K116.7K06.85K0
Inventory002.62M2.64M1.28M589.6K113.4K59.4K191.7K40.1K
Current assets968.0K3.43M3.03M5.38M12.1M8.21M6.54M6.95M5.88M195.6K
Property, plant and equipment42.5K69.3K111.8K235.7K131.1K212.2K236.3K273.2K241.5K295.2K
Total assets3.85M4.45M6.75M9.27M12.9M8.76M7.18M7.22M6.12M490.8K
Accounts payable383.0K269.7K360.4K614.0K791.1K402.9K1.28M631.5K780.3K227.7K
Current liabilities751.0K605.2K903.1K1.70M1.54M986.7K2.07M974.6K848.2K1.38M
Long-term debt28.5K337.1K
Total debt492.4K028.5K28.5K546.6K769.3K773.3K23950.0K
Total liabilities1.59M1.89M1.10M2.07M2.09M1.60M2.42M974.6K848.2K1.38M
Shareholders' equity2.26M2.56M5.66M7.20M10.8M7.17M4.76M6.25M5.28M-893.8K
Shares outstanding1.18M536.9K5.94K3.17M2.13M34.0M8.42M7.42M3.92M723.3K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.18M-7.40M-9.55M-12.8M-11.1M-10.7M-8.59M-7.70M-3.30M-1.32M
Capital spending-17.3K-16.0K-33.9K-202.6K-45.0K-75.3K-43.6K-100.0K-7.86K-7.86K
Free cash flow-5.20M-7.42M-9.58M-13.0M-11.2M-10.8M-8.63M-7.80M-3.31M-1.32M
Cash from investing-3.02M-12.8K-24.7K-202.6K-45.0K-75.3K-43.6K-100.0K-7.86K0
Cash from financing5.73M7.81M7.52M8.40M13.4M11.9M8.34M8.67M8.77M1.44M
Dividends paid-5.23K-840-7.79K-121.1K-395.6K-4.22M
Share buybacks11.5M5.84M7.74M8.59M5.00K
Change in cash-2.47M395.6K-2.06M-4.57M2.23M1.05M-297.2K869.5K5.46M125.8K

Open Financials

Filings

FilingDateTypeFiled with
425Nov 20, 2026Other filingsSEC
425Nov 16, 2026Other filingsSEC
8-K · Current reportNov 16, 2026ResultsSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
425Nov 6, 2026Other filingsSEC
425Nov 5, 2026Other filingsSEC
425Oct 26, 2026Other filingsSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeOct 8, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
S-4 · Registration statementOct 1, 2026Offer documentSEC
425Oct 1, 2026Other filingsSEC
8-K · Current reportOct 1, 2026Material contractSEC
425Sep 25, 2026Other filingsSEC
425Sep 14, 2026Other filingsSEC
425Sep 9, 2026Other filingsSEC
425Sep 9, 2026Other filingsSEC
425Aug 20, 2026Other filingsSEC
425Aug 20, 2026Other filingsSEC
425Aug 17, 2026Other filingsSEC
8-K · Current reportAug 17, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
425Aug 6, 2026Other filingsSEC
425Aug 5, 2026Other filingsSEC
425Aug 4, 2026Other filingsSEC
425Jul 22, 2026Other filingsSEC
425Jul 22, 2026Other filingsSEC
425Jul 17, 2026Other filingsSEC
425Jul 17, 2026Other filingsSEC
8-K · Current reportJul 9, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 29, 2026Big-stake noticeSEC
425Jun 26, 2026Other filingsSEC
8-K · Current reportJun 26, 2026Material contractSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
425Jun 25, 2026Other filingsSEC
425Jun 25, 2026Other filingsSEC
8-K · Current reportJun 25, 2026Current reportSEC
8-K · Current reportMay 28, 2026Material contractSEC
RW · Request to withdraw a registrationMay 26, 2026Other filingsSEC
S-8 · Registration statement for employee plansMay 15, 2026Offer documentSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportApr 21, 2026Current reportSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 25, 2026Current reportSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
8-K · Current reportDec 12, 2025Management or board changeSEC
8-K · Current reportNov 28, 2025Management or board changeSEC
SCHEDULE 13D · Big-stake noticeNov 26, 2025Big-stake noticeSEC
424B4 · ProspectusNov 26, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 14, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
S-3 · Registration statementNov 6, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2025Big-stake noticeSEC
8-K · Current reportOct 29, 2025Material contractSEC
424B5 · ProspectusOct 29, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersOct 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialOct 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 28, 2025Meeting noticeSEC
DOct 24, 2025Other filingsSEC
8-K · Current reportOct 23, 2025Current reportSEC
PRE 14A · Preliminary proxy statementOct 17, 2025Meeting noticeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
8-K/A · Current report, amendedOct 15, 2025Material contractSEC
8-K · Current reportOct 15, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
S-1/A · Registration statement, amendedJul 25, 2025Offer documentSEC
8-K · Current reportJul 23, 2025Current reportSEC
S-1/A · Registration statement, amendedJul 16, 2025Offer documentSEC
8-K · Current reportJul 9, 2025ResultsSEC
S-1 · Registration statementJul 9, 2025Offer documentSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Current reportSEC
8-K · Current reportMay 30, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
DRS · Draft registration statementMay 8, 2025Offer documentSEC
10-K/A · Annual report, amendedApr 4, 2025Annual reportSEC
S-8 · Registration statement for employee plansApr 2, 2025Offer documentSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportNov 22, 2024Current reportSEC
10-Q/A · Quarterly report, amendedNov 21, 2024Quarterly reportSEC
10-Q · Quarterly reportNov 19, 2024Quarterly reportSEC
8-K · Current reportNov 15, 2024ResultsSEC
NT 10-Q · Late filing noticeNov 15, 2024Explanation requestSEC
8-K · Current reportNov 5, 2024Current reportSEC
8-K · Current reportOct 29, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialSep 16, 2024Meeting noticeSEC
DEF 14A · Proxy statementSep 16, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 6, 2024Meeting noticeSEC
4/A · Change in ownership, amendedSep 5, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedSep 5, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 29, 2024Insider tradeSEC
8-K · Current reportAug 28, 2024Current reportSEC
8-K · Current reportAug 23, 2024ResultsSEC
8-K · Current reportAug 16, 2024Current reportSEC
3 · Initial statement of ownershipAug 15, 2024Insider tradeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024Management or board changeSEC
8-K · Current reportAug 9, 2024Management or board changeSEC
DEFA14A · Additional proxy materialJul 17, 2024Meeting noticeSEC
8-K · Current reportJul 17, 2024Current reportSEC
ARS · Annual report to shareholdersJun 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialJun 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementJun 25, 2024Meeting noticeSEC
SC 13G · Big-stake noticeJun 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJun 14, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJun 12, 2024Meeting noticeSEC
8-K · Current reportJun 6, 2024Material contractSEC
424B3 · ProspectusJun 5, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 5, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedMay 31, 2024Offer documentSEC
8-K · Current reportMay 20, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
8-K · Current reportMay 10, 2024ResultsSEC
S-1/A · Registration statement, amendedMay 10, 2024Offer documentSEC
8-K · Current reportMay 3, 2024Current reportSEC
UPLOAD · Letter from the SECApr 29, 2024Other filingsSEC
S-1 · Registration statementApr 19, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 4, 2024Other filingsSEC
424B5 · ProspectusApr 3, 2024Offer documentSEC
424B5 · ProspectusApr 3, 2024Offer documentSEC
CORRESP · Letter to the SECApr 1, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
S-3/A · Registration statement, amendedMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
UPLOAD · Letter from the SECFeb 23, 2024Other filingsSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
4 · Change in ownershipFeb 23, 2024Insider tradeSEC
S-3 · Registration statementFeb 14, 2024Offer documentSEC
424B3 · ProspectusDec 29, 2023Offer documentSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
424B5 · ProspectusAug 14, 2023Offer documentSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
8-K · Current reportAug 10, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 25, 2023Meeting noticeSEC
8-K · Current reportJul 25, 2023Current reportSEC
8-K · Current reportJul 6, 2023Current reportSEC
DEFA14A · Additional proxy materialJul 6, 2023Meeting noticeSEC
ARS · Annual report to shareholdersMay 24, 2023Annual reportSEC
DEFA14A · Additional proxy materialMay 24, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 24, 2023Meeting noticeSEC
4 · Change in ownershipMay 22, 2023Insider tradeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
4 · Change in ownershipMay 3, 2023Insider tradeSEC
8-K · Current reportMay 2, 2023Material contractSEC
424B5 · ProspectusApr 28, 2023Offer documentSEC
S-1MEF · Registration of more shares for the same offeringApr 28, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 28, 2023Other filingsSEC
CORRESP · Letter to the SECApr 24, 2023Other filingsSEC
CORRESP · Letter to the SECApr 24, 2023Other filingsSEC
S-1/A · Registration statement, amendedApr 18, 2023Offer documentSEC
8-K · Current reportApr 18, 2023ResultsSEC
S-1/A · Registration statement, amendedApr 18, 2023Offer documentSEC
UPLOAD · Letter from the SECApr 7, 2023Other filingsSEC
S-1 · Registration statementMar 30, 2023Offer documentSEC
S-8 · Registration statement for employee plansMar 16, 2023Offer documentSEC
10-K · Annual reportMar 16, 2023Annual reportSEC
8-K · Current reportMar 14, 2023ResultsSEC
SC 13G · Big-stake noticeMar 10, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
8-K · Current reportDec 23, 2022Management or board changeSEC
8-K · Current reportDec 19, 2022Material contractSEC
4 · Change in ownershipDec 13, 2022Insider tradeSEC
8-K · Current reportDec 8, 2022Current reportSEC
8-K · Current reportDec 2, 2022Meeting outcomeSEC
4 · Change in ownershipNov 28, 2022Insider tradeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
DEFA14A · Additional proxy materialOct 17, 2022Meeting noticeSEC
DEF 14A · Proxy statementOct 17, 2022Meeting noticeSEC

This page holds 200 of 551 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ENDRA Life Sciences Inc.’s releases · as of Oct 23, 2025

Common shares
1,499,912
Fully diluted
1,499,912

Fully diluted

LineShares
Common shares1,499,912

Warrants and options

Lot
Warrants · US$6.32 · expire about Oct 2030

Share count over time

CountShares
Nov 22, 20261,499,912

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Altium Capital Management LLC54,5283.6%US$325KSep 30, 2026
Citizens Financial Group Inc28,4001.9%US$169KSep 30, 2026
Citadel20,7451.4%US$124KSep 30, 2026
Renaissance Technologies18,7641.3%US$112KSep 30, 2026
Vanguard17,4601.2%US$104KSep 30, 2026
Geode Capital14,9100.99%US$88,863Sep 30, 2026
UBS5,9420.40%US$35,414Sep 30, 2026
Morgan Stanley3,5460.24%US$21,134Sep 30, 2026
Citigroup Inc1,0780.07%US$6,425Sep 30, 2026
Tower Research Capital LLC (TRC)8830.06%US$5,262Sep 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Northwestern Mutual Wealth Management Co19<0.01%US$113Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund14,5800.97%US$80,190May 31, 2026
Vanguard Extended Market Index Fund7,3390.49%US$39,117Jun 30, 2026
Fidelity Series Total Market Index Fund1,5970.11%US$8,784May 31, 2026

Big stakes

StakeStakeSharesDateFiling
ASP Isotopes Inc.15.10%254KOct 1, 2026Schedule 13D
Salt Rock Capital Partners LLP7.40%111KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anthony DiGiandomenico
Other companies: Illumination Acquisition Corp I (Director · Since at least Feb 26, 2026); ClearSign Technologies Corporation (Director · Since at least May 22, 2025); eXoZymes Inc. (Board Member · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Co-Founder, Head of New Venture Discovery · Since at least Jul 25, 2023); Provention Bio Inc (Director · Jul 3, 2018 – May 15, 2020 · Past); Cue Biopharma, Inc. (Director · Dec 18, 2017 – Jan 2, 2019 · Past); Charlie's Holdings, Inc. (Director · Aug 4, 2006 – Aug 27, 2012 · Past)
Director · Since at least May 8, 2017
David R. Wells
Other companies: Fusemachines Inc. (Chief Financial Officer · Since at least Sep 1, 2026); Functional Brands, Inc. (Chief Financial Officer, Director · Since at least May 18, 2026); HeartSciences Inc. (Board Member · Since at least Dec 28, 2022); Envoy Medical, Inc. (Chief Financial Officer · Sep 29, 2023 – Oct 15, 2023 · Past); Sionix Corporation (President, CFO, Director · Dec 16, 2009 – May 7, 2012 · Past)
Chief Financial Officer · May 8, 2017 – Apr 5, 2021 · Past
Alexander Tokman
Other companies: MicroVision, Inc. (President and CEO, Director · Apr 13, 2006 – Feb 8, 2017 · Past)
CEO & Director · Since at least May 8, 2017
Lou Basenese
Other companies: ClearSign Technologies Corporation (Director · Since at least May 22, 2025)
Director · Since at least Apr 9, 2020
Renaud Bertrand Maloberti
Other companies: Bionik Laboratories Corp. (Chief Commercial Officer · Jun 11, 2018 – Jun 11, 2018 · Past)
Chief Commercial Officer · May 28, 2019 – Mar 28, 2022 · Past
Lou BaseneseDirector · Since at least Nov 4, 2026
Michael HarshDirector · Since at least Jun 11, 2025
Richard JacrouxChief Financial Officer · Since at least Nov 22, 2024
Scott SoberHead of Operations · Since at least Nov 4, 2026
Ziad RouagHead of Clinical and Regulatory · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about ENDRA Life Sciences Inc.